Medcxy

Product dossierBuilt from registrations, label text and platform-curated data

saypha® ChiQ™P250021

Ask about this product

saypha® ChiQ™ is a Hyaluronic acid filler product, registered by Croma-Pharma GmbH. Linked registrations: US P250021. First approved in US on 2026-06-12 (P250021). Data as of 2026-10-27.

  • Regulatory classHyaluronic acid filler · class not determined
  • HolderCroma-Pharma GmbH
  • JurisdictionsUS
  • Updated2026-10-27 · v1

Registration and basics are public; findings and prices need an account

Registration and basics

saypha® ChiQ™

Product
Regulatory class
Not determined (no verified registration linked)Could not verify
Category
Hyaluronic acid filler
US · FDA PMA
P250021
Registrant
Croma-Pharma GmbH
First approval
2026-06-12
This certificate issued
2026-06-12
Checked against official page
Not yet checked field by field against the live official page

Public: fields from the registration record.

Label facts by jurisdiction

What each jurisdiction's label says for the same attribute; gaps are marked Not reported, irrelevant ones N/A

No data yet

Registration timeline

  1. US

    P250021 first approved

  2. US

    P250021 · P250021/S001

    Normal 180 Day Track No User Fee｜Postapproval Study Protocol｜Approval of the scale validation protocol for the post-approval study (PAS) ref…

  3. US

    P250021 · P250021/S002

    Normal 180 Day Track No User Fee｜Postapproval Study Protocol｜Approval of the protocol for the post-approval study (PAS) referenced above. Th…

First approval, this certificate's issue date (updated after renewals or changes), changes and expiry are listed separately; a missing first approval means it was not obtained from an official source. Up to 6 recent changes per registration; click the number for the full record.

Cross findings · Price observations

Sign in to see findings and prices

Findings and prices stay out of indexable pages.

Sign in to view

Recent changes

2
  • P250021: Normal 180 Day Track No User Fee｜Postapproval Study Protocol｜Approval of the pro…2026-10-08
  • P250021: Normal 180 Day Track No User Fee｜Postapproval Study Protocol｜Approval of the sca…2026-10-07

Sources

1